Nanite is at the forefront of non-viral gene delivery technology, utilizing AI-driven polymer nanoparticles (PNPs) to enhance the precision and safety of genetic therapies. Their innovative SAYER™ platform integrates computational design, rapid synthesis, and first-principles characterization to create PNPs that are specifically engineered for targeted tissue delivery. This approach allows for the optimization of polymer nanoparticles to achieve high tissue specificity and expression while minimizing toxicity and immunogenicity. By employing high-throughput synthesis and advanced algorithms, Nanite can efficiently screen and analyze a diverse array of PNPs, ensuring meticulous characterization and robust data generation.

The company’s focus on resorbable and safe polymer nanoparticles positions them as a promising alternative to traditional viral vectors and lipid nanoparticles. Nanite's PNPs are designed to be biologically compatible, reducing immune responses and enabling repeat dosing with transient genetic payloads. Their modular design allows for rapid prototyping and customization to meet specific delivery needs, while their scalable manufacturing capabilities ensure that these advanced delivery systems can be produced efficiently and cost-effectively. With a commitment to enhancing the reliability and effectiveness of gene therapies, Nanite is setting new standards in the field of genetic drug delivery.

United States

Nanite is a next-generation non-viral gene delivery company developing a new class of programmable polymer nanoparticles for a range of modalities and indications. The company’s AI-driven platform, SAYER, combines cutting-edge high-throughput experimental and computational methods to design fit-for-purpose delivery vehicles delivering a broad range of genetic cargoes with tissue specificity.

Nanite

Company Details